Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Articles

Page Path
HOME > J Korean Cancer Assoc > Ahead-of print articles > Article
Original Article Normal Brain-Sparing Radiotherapy versus Whole Brain Radiotherapy for Multiple Brain Metastasis from Non–Small Cell Lung Cancer
Sangjoon Park1,2orcid, Jaeho Cho1, Kyung Hwan Kim1, Hong In Yoon1, Chang Geol Lee1,orcid

DOI: https://doi.org/10.4143/crt.2024.679
Published online: December 3, 2024

1Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Korea

2Institute for Innovation in Digital Healthcare, Yonsei University, Seoul, Korea

Correspondence: Chang Geol Lee, Department of Radiation Oncology, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Tel: 82-2-2228-8114 E-mail: CGLEE1023@yuhs.ac
• Received: July 23, 2024   • Accepted: December 2, 2024

Copyright © 2025 by the Korean Cancer Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 680 Views
  • 50 Download
Full Article

Download PDF Download PDF

  • Purpose
    The efficacy and lower neurotoxicity of normal brain-sparing radiotherapy (NBS-RT) with systemic therapy in treating multiple brain metastases from non–small cell lung cancer (NSCLC) is underexplored. This study compares whole brain radiotherapy (WBRT) and NBS-RT for multiple brain metastases in NSCLC, focusing on treatment outcomes and leukoencephalopathy.
  • Materials and Methods
    This retrospective study included 503 patients with NSCLC with multiple brain metastases at a single center, treated with either WBRT or NBS-RT. Post-RT treatments included chemotherapy, targeted therapy, or immunotherapy. Main outcomes measured were intracranial control, overall survival (OS), and leukoencephalopathy incidence.
  • Results
    In this study, 441 patients received WBRT and 62 received NBS-RT, with median ages of 62 and 61 years, respectively. A significant portion of both groups, 77.3% in WBRT and 80.6% in NBS-RT, received post-RT systemic therapy. The median number of brain metastases was 10 for WBRT and 12 for NBS-RT, with median maximal diameters of 11.7 mm in WBRT and 14.4 mm in NBS-RT. After a median follow-up of 10.9 months for WBRT and 11.8 months for NBS-RT, there were no significant differences in intracranial progression (p=0.516) or OS (p=0.492) between the groups. However, WBRT patients had a higher incidence of leukoencephalopathy than NBS-RT patients (p=0.013).
  • Conclusion
    NBS-RT combined with systemic therapy was as effective in treating multiple brain metastases as WBRT and was less toxic. NBS-RT-based strategies deserve further investigation in a prospective setting.
  • Key words: Brain neoplasms, Leukoencephalopathies, Non-small-cell lung carcinoma, Radiotherapy
Recently developed treatments for non–small cell lung cancer (NSCLC), including molecular targeted agents, immunotherapy, and cytotoxic chemotherapy, have significantly improved patient outcomes [1,2]. Despite a limited ability to cross the blood-brain barrier (BBB) [3], some research has suggested that these agents may be useful for treating brain metastases in patients with NSCLC [4].
While whole brain radiotherapy (WBRT) has long been the standard therapy for brain metastases in NSCLC, the steep cognitive decline that typically ensues has led to a shift towards treating patients with 1-3 small lesions (< 3 cm) with localized therapies such as stereotactic radiosurgery (SRS). While this has inspired many high-quality trials comparing WBRT to normal brain-sparing radiotherapy (NBS-RT) like SRS [5-12], large (≥ 3 cm) and multiple (≥ 4) lesions (henceforward referred to as multiple metastatic disease) have been ignored in such trials. WBRT is still preferred for multiple metastatic disease due to its expected benefit in enhancing intracranial control. However, the feasibility and outcomes of NBS-RT in such patients have remained inadequately investigated [13-15], despite its potential for intracranial tumor control with effective systemic therapy, particularly in the era of advanced NSCLC treatments.
To evaluate the feasibility of NBS-RT as a treatment for multiple brain metastases in NSCLC, we aimed to compare the treatment outcomes and the risk profiles of NBS-RT and WBRT in the previously underexplored cohort of patients having NSCLC with multiple metastatic disease involving the brain. These patients were treated with either WBRT or NBS-RT in multiple fractions, a treatment paradigm that has rarely been attempted before.
1. Patient eligibility
We retrospectively analyzed medical records from 819 patients diagnosed with NSCLC and treated for brain metastases from August 2016 to June 2023. After exclusions (fewer than 4 metastases and maximum diameter < 3 cm [n=107], previous WBRT [n=16], incomplete radiotherapy [RT; n=12], and absence of post-treatment magnetic resonance imaging [MRI] data [n=181]), 503 patients were eligible for analysis (S1 Fig.).
2. Radiotherapy
For each patient, the radiation dose administered to the whole brain and bilateral hippocampi was calculated. All patients underwent either fractionated WBRT or NBS-RT (Supplementary Methods). WBRT was delivered using 2D/3D conformal techniques or intensity-modulated radiotherapy (IMRT), with a standard dose of 20-30 Gy over 5-10 fractions, plus a possible gross tumor volume (GTV) boost of 5-9 Gy in select cases (S2A Fig.). IMRT involved a single prescription dose to the whole brain or a simultaneous integrated boost (SIB) around the GTV, over a total of 5-15 fractions (S2B Fig.). Hippocampus-sparing WBRT was applied when feasible, considering patient survival and planning parameters (S2C Fig.). For NBS-RT, the planning target volume (PTV) was delineated with a 3-5-mm margin around the GTV, prescribing 25-30 Gy to the PTV or an additional SIB-administered boost of 3-12.5 Gy to the GTV, delivered over 5-15 fractions (S2D Fig., S3 Table).
3. Evaluation of RT-related leukoencephalopathy
Leukoencephalopathy evaluation was based on MRI examinations performed > 1 month after the completion of RT. The diagnostic process included the clear identification of characteristic diffuse hyperintensities in the periventricular white matter on T2/fluid-attenuated inversion recovery imaging (S4 Fig.) [16]. RT-related leukoencephalopathy was defined by the appearance of new lesions observed when comparing MRI scans conducted before and after RT. Preexisting changes in the T2 white-matter signal were not considered indicative of leukoencephalopathy. Leukoencephalopathy was diagnosed only when these findings were consistently observed in at least two consecutive follow-up imaging studies. All evaluations were performed by boardcertified neuroradiologists. Details of the number of follow-up MRI scans and the follow-up intervals are provided in S5 Table.
4. Statistical analysis
The interval from the initiation of RT to intracranial failure (local and distant) and the occurrence of leukoencephalopathy was used to estimate the time-to-intracranial failure and the time-to-leukoencephalopathy, and the cumulative incidences were analyzed with the competing risks model [17]. Overall survival (OS) was defined as the period from the start of treatment to either any cause of death or the last observation. Univariable and multivariable analyses were conducted using Fine and Gray regression and Cox proportional hazards regression (Supplementary Methods). To adjust for differences in characteristics between groups, propensity score matching (PSM) was employed (Supplementary Methods). Statistical was 10.8 months (interquartile range [IQR], 7.4 to 17.8 months). Further significance was established for two-sided p-values < 0.05. All analysis was performed using R software ver. 4.3.1 (R Foundation for Statistical Computing).
1. Patient characteristics
In this study, 441 and 62 patients were enrolled in the WBRT and NBS-RT groups, respectively. Baseline patient and treatment characteristics for both cohorts are detailed in Table 1.
A comparative analysis of the groups revealed no significant differences in intracranial tumor burden or tumor characteristics, including the total number of parenchymal metastases (median, 10; IQR, 5 to 28 in WBRT group vs. 12; IQR, 6 to 32 in NBS-RT group) and the maximal diameter of metastases (mm) (median, 11.7; IQR, 6.7 to 20.1 in WBRT group vs. 14.4; IQR, 8.2 to 26.1 in NBS-RT group). An exception was the lower incidence of leptomeningeal seeding (LMS) (37.6% vs. 21.0% in WBRT and NBS-RT groups, respectively; p=0.015) and a greater total prescription dose (biologically effective dose in Gy) in the NBS-RT group compared to the WBRT group (median, 39; IQR, 37.5 to 47.2 in WBRT group vs. 43.9; IQR, 43.9 to 47.2 in NBS-RT group; p < 0.001). Given these significant differences, PSM was implemented. Following PSM, there were no significant differences in characteristics between the two groups (S6 Table). Most patients in both groups underwent systemic therapy after RT, with 77.3% (341 out of 441) in the WBRT group and 80.6% (50 out of 62) in the NBS-RT group receiving any type of systemic therapy after RT.
2. Intracranial tumor control and OS
The median (IQR) follow-up duration in this study was 10.9 (6.4-21.0) and 11.8 (7.3-23.2) months for the WBRT and NBS-RT groups, respectively. There was no significant difference in the cumulative incidence of intracranial progression between the groups (1-year cumulative incidence, 47.4%; 95% confidence interval [CI], 42.5% to 52.1% in WBRT group vs. 49.0%; 95% CI, 35.8% to 60.9% in NBS-RT group; p=0.581 for competing risk) (Fig. 1A). In the final multivariable Cox model, older age (hazard ratio [HR], 0.68; 95% CI, 0.52 to 0.89; p=0.004) and targeted therapy after RT (HR, 0.67; 95% CI, 0.51 to 0.89; p=0.005) were significantly associated with better intracranial tumor control. The RT type had no significant impact on intracranial tumor progression (Table 2).
There was no significant difference in OS between the WBRT (median, 12.1 months [95% CI, 10.9 to 13.8]) and NBS-RT (median, 12.3 months [95% CI, 10.0 to 22.5]; p=0.491 for log-rank) groups (Fig. 1B). Multivariable Cox regression analysis identified older age (HR, 1.28; 95% CI, 1.08 to 1.52; p=0.004) and previous gamma knife surgery (GKS) (HR, 1.36; 95% CI, 1.04 to 1.79; p=0.025) as being associated with poorer OS. Conversely, anaplastic lymphoma kinase (ALK) mutation (HR, 0.49; 95% CI, 0.29 to 0.81; p=0.006), a higher total prescribed RT dose (HR, 0.84; 95% CI, 0.71 to 1.00; p=0.047), and undergoing targeted therapy after RT (HR, 0.66; 95% CI, 0.52 to 0.83; p < 0.001) were associated with improved OS. The presence of LMS showed a borderline-significant association with poorer OS (HR, 1.27; 95% CI, 0.98 to 1.64; p=0.069). The RT type was not a significant factor for OS (Table 2).
Post-PSM, the comparison between the groups showed no significant difference in the cumulative incidence of intracranial progression (1-year cumulative incidence, 44.2% [95% CI, 31.0% to 56.5%] vs. 48.1% [95% CI, 34.9% to 60.2%] in the WBRT and NBS-RT group, respectively; p=0.398 for competing risk) (S7A Fig.). OS (median, 12.3 [95% CI, 9.9 to 22.6] months vs. 12.3 [95% CI, 10.0 to 22.5] months in the WBRT and NBS-RT groups, respectively; p=0.758) showed no significant difference between the groups (S7B Fig.).
Subgroup analysis revealed no significant difference in intracranial tumor control or OS between patients without and with LMS (S8 Fig.), while patients receiving NBS-RT without post-RT systemic therapy exhibited significantly worse intracranial tumor control than the patients receiving WBRT without post-RT systemic therapy (S9A Fig.). Conversely, in patients who received systemic therapy post-RT, there was no significant difference in intracranial tumor control between the NBS-RT and WBRT groups (S9C Fig.). There were no significant differences in OS between NBS-RT and WBRT groups, regardless of post-RT systemic therapy (S9B and S9D Fig.). A subgroup analysis of patients with extensive brain metastases, defined as having more than 10 parenchymal metastases, also showed no significant differences in intracranial tumor control or OS between the WBRT and NBS-RT groups (S10A and S10B Fig.).
3. Incidence of leukoencephalopathy
The incidence of leukoencephalopathy was significantly higher in the WBRT group than in the NBS-RT group (1-year cumulative incidence, 12.5%; 95% CI, 9.5% to 15.9% in WBRT vs. 6.9%; 95% CI, 2.2% to 15.5% in NBS-RT; p=0.006 for competing risk) (Fig. 1C). In patients who developed leukoencephalopathy, the median time to radiographic diagnosis r detailed analysis by RT technique demonstrated significant differences in leukoencephalopathy incidence between the conventional WBRT, hippocampus-sparing WBRT, and NBSRT groups (1-year cumulative incidence, 11.9%; 95% CI, 8.3% to 16.3% with conventional WBRT vs. 13.4%; 95% CI, 8.6% to 19.3% with hippocampus-sparing WBRT vs. 6.9%; 95% CI, 2.2% to 15.5% with NBS-RT; p=0.017 for competing risk) (Fig. 1D). Patients receiving NBS-RT showed a significantly lower incidence of leukoencephalopathy than those receiving conventional WBRT (p=0.011 for competing risk) or hippocampus-sparing WBRT (p=0.004 for competing risk). However, there was no significant difference in the incidence of leukoencephalopathy between the conventional WBRT and hippocampus-sparing WBRT groups (p=0.450 for competing risk).
In the final multivariable competing risk regression model, WBRT was associated with an increased risk of developing leukoencephalopathy (HR, 3.51; 95% CI, 1.27 to 9.71; p=0.016) compared to NBS-RT, while post-RT immunotherapy was associated with a decreased risk of developing leukoencephalopathy (HR, 0.17; 95% CI, 0.04 to 0.66; p=0.011) (Table 3).
In the subgroup analysis focused on assessing the risk of leukoencephalopathy associated with WBRT, older patients, those without prior GKS, those without LMS, and those who did not receive pre-RT systemic therapy showed an increased risk of developing leukoencephalopathy (S11 Table).
To the best of our knowledge, this study is the first to compare outcomes in patients receiving NBS-RT in multiple fractions to those achieved in patients undergoing WBRT for multiple brain metastases in NSCLC. This patient population has historically been treated exclusively with WBRT and the potential benefits of lower-toxicity RT have been largely unexplored. Our findings demonstrated that NBS-RT can achieve outcomes in NSCLC (OS and intracranial tumor control) comparable to those of WBRT, when combined with improved systemic therapy. We observed a significantly lower risk of leukoencephalopathy with NBS-RT, which appears to be associated with the reduced brain dose identified in the dosimetric analysis (Supplementary Results, S12 and S13 Tables).
Historically, poor survival rates led to treatments for patients with distant metastases, including brain metastases, that primarily emphasized survival outcomes, often at the expense of quality of life (QoL). However, recent advancements in NSCLC therapies, especially targeted therapies for specific cancer genes and proteins [18,19], as well as immunotherapies involving checkpoint inhibitors [20,21], have significantly improved survival outcomes, thus elevating the importance of QoL in patient care.
For over half a century, WBRT has been the standard treatment for brain metastases. However, a significant proportion of patients undergoing WBRT develop leukoencephalopathy on long-term follow-up [22,23], often accompanied by cognitive decline. The advent of sophisticated RT techniques has prompted more investigation of localized gross tumor-targeted approaches like SRS as potential alternatives to WBRT for patients with a limited number of small brain metastases. This shift in approach has resulted in a multitude of randomized controlled trials, aimed at investigating various treatment combinations, including WBRT alone, SRS alone, and combined WBRT/SRS [5-12,24-26]. These trials have consistently demonstrated that while survival outcomes with SRS alone and WBRT are not significantly different, cognitive decline is significantly less pronounced with SRS alone and intracranial tumor control is significantly better with WBRT. The latter benefit is commonly attributed to the effective management of presumed micrometastases, which would have otherwise led to intracranial failure.
Patients with multiple metastases have not traditionally been considered candidates for NBS-RT. WBRT was considered appropriate in such circumstances. However, advancements in systemic therapies for NSCLC change the context to highlight the potential benefits of NBS-RT in these patients, and paradoxically challenge the orthodox view that good intracranial control is attainable only with WBRT. It suggests that NBS-RT for multiple metastases combined with effective systemic therapy could be sufficient for intracranial tumor control comparable to WBRT. In this context, we employed NBS-RT, targeting the GTV to spare normal brain tissue, similar to SRS, while incorporating the benefits of multifractionation, as in WBRT, to reduce treatment-related toxicity. Central to this strategy is the focus on gross tumor (like SRS) to reduce the risk of cognitive impairment commonly associated with WBRT, while simultaneously facilitating the multi-fraction treatment of multiple lesions that often pose significant challenges in conventional SRS. The recent use of fractionated SRS for large metastases shares conceptual similarities with our approach [15]. However, it primarily targets larger tumors and is not specifically designed for treating multiple brain metastases.
Our approach attained intracranial tumor control and OS comparable to those seen with WBRT and with significantly reduced radiation damage, as manifested by the decreased incidence of leukoencephalopathy. This finding contrasts with previous results suggesting the superiority of WBRT in intracranial control over only treating the gross tumor. We attributed this contrast to the unique patient profiles in our study compared to earlier trials. Our focus on patients with multiple metastatic disease (generally excluded in previous trials) allowed us to irradiate a substantial portion of the brain with NBS-RT. This is unattainable when treating only 1-3 small lesions with SRS; hence, such treatments crucially preclude the potential for widespread BBB disruption possible with our regimen. This led us to hypothesize that systemic therapy might be more effective for intracranial tumor control following such BBB disruption [27]. The subgroup analysis supported this hypothesis, showing that patients not receiving systemic therapy post-RT had a higher incidence of intracranial failure with NBS-RT than WBRT. In contrast, there was no significant difference in intracranial tumor control between NBS-RT and WBRT in patients who received systemic therapy post-RT. Furthermore, patients in our study, treated more recently, frequently received advanced targeted therapies for epidermal growth factor receptor (EGFR), ALK, and ROS1 [18,19] mutations and immunotherapies [20,21], representing an improved systemic treatment regimen than those treated in earlier trials [5-12,24-26]. Combined, the use of advanced systemic therapy post-RT in our study likely played a key role in achieving intracranial tumor control with NBS-RT, comparable to WBRT. This finding aligns with prior research showing the benefits of post-RT systemic therapy over standalone systemic therapy [28,29].
A large proportion of patients with brain metastases eventually develop intracranial progression (281 out of 503 in our study). In those who have undergone WBRT, reirradiation options are frequently constrained due to accumulated high doses in the brain parenchyma, which heightens the risk of adverse effects. In contrast, NBS-RT conserves brain regions previously underexposed to radiation, allowing for the delivery of more effective doses for tumor control. This is illustrated in a representative case (S14 Fig.) where a patient initially treated with NBS-RT experienced progression in an area not previously irradiated. The patient subsequently received another round of NBS-RT at a full dose, effectively targeting the progressed area.
This study’s retrospective design presents some limitations that caution against overestimating its results. Firstly, its retrospective nature resulted in an imbalance in patient numbers and characteristics between the WBRT and NBS-RT groups. Although PSM was used to address these disparities, it led to a smaller patient cohort and diminished statistical reliability. Our study indicated no significant differences in intracranial control post-PSM, but a larger cohort might reveal significant differences. In this study, MRI-detected leukoencephalopathy was used as an objective surrogate endpoint. However, it is important to recognize that radiologically confirmed radiation-induced leukoencephalopathy does not always correlate with immediate clinical symptoms such as cognitive decline. In our cohort, only 25.3% of patients with leukoencephalopathy presented with associated symptoms (S15 Table). Despite this, long-term studies have indicated that even asymptomatic leukoencephalopathy observed on imaging can be associated with delayed cognitive deterioration and diminished QoL [30]. Therefore, imaging findings can be considered a reasonable surrogate for clinically meaningful leukoencephalopathy in the absence of immediate symptoms. A further challenge lies in distinguishing cognitive decline caused by leukoencephalopathy from that due to brain metastasis progression, particularly in patients receiving WBRT. Many patients eventually experience intracranial progression, complicating the accurate assessment of neurological symptoms related specifically to leukoencephalopathy. Due to the retrospective nature of this study, precise evaluation of symptomatology was not feasible. As such, we were compelled to rely on imaging-based surrogates, which represents a key limitation of this study. Lastly, the process of delineating all metastases for NBS-RT can be labor-intensive with numerous metastases, emphasizing the need for emerging artificial intelligence models for precise GTV contouring.
In this retrospective cohort study, NBS-RT for NSCLC with multiple brain metastases, when combined with post-RT systemic therapy, showed outcomes comparable to WBRT, with a lower leukoencephalopathy risk. However, given the study’s limitations, these findings are preliminary. Prospective studies are needed to confirm the viability of NBS-RT for multiple brain metastases from NSCLC, especially when used alongside systemic therapy, in terms of patient cognitive function and QoL.
Supplementary materials are available at Cancer Research and Treatment website (https://www.e-crt.org).
crt-2024-679_S1_Fig.pdf
crt-2024-679_S2_Fig.pdf
crt-2024-679_S3_Table.pdf
crt-2024-679_S4_Fig.pdf
crt-2024-679_S5_Table.pdf
crt-2024-679_S6_Table.pdf
crt-2024-679_S7_Fig.pdf
crt-2024-679_S8_Fig.pdf
crt-2024-679_S9_Fig.pdf
crt-2024-679_S10_Fig.pdf
crt-2024-679_S11_Table.pdf
crt-2024-679_S12_Table.pdf
crt-2024-679_S13_Table.pdf
crt-2024-679_S14_Fig.pdf
crt-2024-679_S15_Table.pdf
crt-2024-679_Supplementary_Methods.pdf

Ethical Statement

This study was conducted in accordance with the principles of the Declaration of Helsinki and received approval from the Institutional Review Board of Severance Hospital (approval number: 4-2023-0309). Due to the retrospective nature of the research, the requirement for informed consent was waived. Furthermore, this study adhered to the guidelines of the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE).

Author Contributions

Conceived and designed the analysis: Park S, Lee CG.

Collected the data: Park S, Cho J, Kim KH, Yoon HI, Lee CG.

Contributed data or analysis tools: Park S, Kim KH.

Performed the analysis: Park S.

Wrote the paper: Park S, Cho J, Kim KH, Yoon HI, Lee CG.

Conflicts of Interest

Conflict of interest relevant to this article was not reported.

Funding

S.P. received financial support from the Basic Science Research Program through the National Research Foundation funded by the Ministry of Education of Korea under Grant RS-2023-00242164.

Fig. 1.
Treatment outcomes and cumulative incidence of leukoencephalopathy according to radiotherapy (RT) group. Cumulative incidence of intracranial tumor progression (A), overall survival (B), and cumulative incidence of leukoencephalopathy (C) according to RT group. Cumulative incidence of leukoencephalopathy by detailed RT technique (D). NBS-RT, normal brain-sparing radiotherapy; WBRT, whole brain radiotherapy.
crt-2024-679f1.jpg
Table 1.
Patient characteristics
Characteristic WBRT (n=441) NBS-RT (n=62) p-value
Age (yr) 62 (54-68) 61 (51-70) 0.903
Sex
 Male 201 (45.6) 27 (43.5) 0.869
 Female 240 (54.4) 35 (56.5)
Previous GKS
 No 337 (76.4) 41 (66.1) 0.110
 Yes 104 (23.6) 21 (33.9)
Previous surgery
 No 415 (94.1) 59 (95.2) > 0.99
 Yes 26 (5.9) 3 (4.8)
No. of parenchymal metastasis 10 (5-28) 12 (6-32) 0.189
Max diameter of metastasis 11.7 (6.7-20.1) 14.4 (8.2-26.1) 0.070
Leptomeningeal seeding
 Absent 275 (62.4) 49 (79.0) 0.015
 Present 166 (37.6) 13 (21.0)
Pathology
 Adenocarcinoma 425 (96.4) 59 (95.2) 0.718
 Others 16 (3.6) 3 (4.8)
EGFR
 Negative 132 (29.9) 20 (32.3) 0.798
 Positive 290 (65.8) 39 (62.9)
 Unknown 19 (4.3) 3 (4.8)
ALK
 Negative 324 (73.5) 41 (66.1) 0.763
 Positive 26 (5.9) 4 (6.5)
 Unknown 91 (20.6) 17 (27.4)
ROS1
 Negative 263 (59.6) 30 (48.4) 0.227
 Positive 50 (11.3) 10 (16.1)
 Unknown 128 (29.0) 22 (35.5)
PD-L1 expression (%) 1.0 (0.0-15.0) 3.5 (0.0-50.0) 0.253
BED (Gy) 39 (37.5-47.2) 43.9 (43.9-47.2) < 0.001
Pre-RT cytotoxic chemotherapy
 No 363 (82.3) 47 (75.8) 0.289
 Yes 78 (17.7) 15 (24.2)
Pre-RT targeted therapy
 No 280 (63.5) 44 (71.0) 0.313
 Yes 161 (36.5) 18 (29.0)
Pre-RT immunotherapy
 No 400 (90.7) 56 (90.3) > 0.99
 Yes 41 (9.3) 6 (9.7)
Post-RT cytotoxic chemotherapy
 No 323 (73.2) 39 (62.9) 0.122
 Yes 118 (26.8) 23 (37.1)
Post-RT targeted therapy
 No 228 (51.7) 36 (58.1) 0.422
 Yes 213 (48.3) 26 (41.9)
Post-RT immunotherapy
 No 396 (89.8) 54 (87.1) 0.669
 Yes 45 (10.2) 8 (12.9)
Systemic regimen change
 No 394 (89.3) 54 (87.1) 0.754
 Yes 47 (10.7) 8 (12.9)
Intrathecal chemotherapy
 No 430 (97.5) 62 (100) 0.375
 Yes 11 (2.5) 0

Values are presented as median (IQR) or number (%). ALK, anaplastic lymphoma kinase; BED, biologically effective dose; EGFR, epidermal growth factor receptor; GKS, gamma knife radiosurgery; IQR, interquartile range; NBS-RT, normal brain-sparing radiotherapy; PD-L1, programmed death-ligand 1; ROS1, c-ros oncogene 1; RT, radiotherapy; WBRT, whole brain radiotherapy.

Table 2.
Competing risk regression for intracranial progression and Cox proportional hazards regression analysis for overall survival
Variable Intracranial progression
 Overall survival
Univariable
 Multivariable
 Univariable
 Multivariable
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Age (yr)
 < 60 1 (reference) 1 (reference) 1 (reference) 1 (reference)
 ≥ 60 0.77 (0.65-0.91) 0.002 0.68 (0.52-0.89) 0.004 1.17 (1.01-1.35) 0.034 1.28 (1.08-1.52) 0.004
Sex
 Male 1 (reference) - 1 (reference) -
 Female 1.13 (0.89-1.42) 0.318 - - 0.98 (0.80-1.19) 0.813 - -
Previous GKS
 No 1 (reference) - 1 (reference) 1 (reference)
 Yes 0.95 (0.72-1.27) 0.751 - - 1.50 (1.19-1.88) < 0.001 1.36 (1.04-1.79) 0.025
Previous surgery
 No 1 (reference) - 1 (reference) 1 (reference)
 Yes 1.35 (0.85-2.15) 0.201 - - 0.53 (0.34-0.85) 0.008 0.67 (0.38-1.17) 0.157
No. of parenchymal metastasis
 < 10 1 (reference) - 1 (reference) -
 ≥ 10 1.05 (0.89-1.24) 0.535 - - 1.09 (0.94-1.25) 0.241 - -
Max diameter of metastasis (mm)
 < 20 1 (reference) - 1 (reference) -
 ≥ 20 1.04 (0.83-1.32) 0.726 - - 0.71 (0.57-0.88) 0.002 - -
Leptomeningeal seeding
 No 1 (reference) - 1 (reference) 1 (reference)
 Yes 1.07 (0.84-1.37) 0.575 - - 1.34 (1.09-1.66) 0.006 1.27 (0.98-1.64) 0.069
Pathology
 Adenocarcinoma 1 (reference) - 1 (reference) -
 Others 0.81 (0.39-1.68) 0.569 - - 1.35 (0.81-2.27) 0.253 - -
EGFR
 Negative 1 (reference) - 1 (reference) -
 Positive 1.05 (0.82-1.36) 0.687 - - 1.05 (0.82-1.36) 0.687 - -
ALK
 Negative 1 (reference) - 1 (reference) 1 (reference)
 Positive 0.94 (0.59-1.50) 0.797 - - 0.94 (0.59-1.50) 0.797 0.49 (0.29-0.81) 0.006
ROS1
 Negative 1 (reference) - 1 (reference) -
 Positive 1.27 (0.88-1.84) 0.204 - - 1.27 (0.88-1.84) 0.204 - -
PD-L1 expression (%)
 < 1 1 (reference) 1 (reference) 1 (reference) -
 ≥ 1 0.89 (0.74-1.07) 0.199 0.80 (0.61-1.06) 0.116 0.89 (0.74-1.07) 0.199 - -
Radiotherapy
 NBS-RT 1 (reference) - 1 (reference) -
 WBRT 0.89 (0.64-1.25) 0.516 - - 1.11 (0.82-1.51) 0.492 - -
BED (Gy)
 ≤ 39 1 (reference) - 1 (reference) 1 (reference)
 > 39 0.98 (0.83-1.16) 0.824 - - 0.77 (0.67-0.89) 0.001 0.84 (0.71-1.00) 0.047
Pre-RT cytotoxic chemotherapy
 No 1 (reference) - 1 (reference) -
 Yes 0.82 (0.59-1.14) 0.246 - - 1.68 (1.30-2.16) < 0.001 - -
Pre-RT targeted therapy
 No 1 (reference) - 1 (reference) -
 Yes 0.78 (0.61-0.99) 0.044 - - 0.80 (0.65-0.99) 0.042 - -
Pre-RT immunotherapy
 No 1 (reference) 1 (reference) 1 (reference) -
 Yes 0.70 (0.44-1.11) 0.126 0.68 (0.42-1.12) 0.130 1.91 (1.36-2.66) < 0.001 - -
Post-RT cytotoxic chemotherapy
 No 1 (reference) - 1 (reference) -
 Yes 0.96 (0.74-1.25) 0.761 - - 1.28 (1.03-1.60) 0.025 - -
Post-RT targeted therapy
 No 1 (reference) 1 (reference) 1 (reference) 1 (reference)
 Yes 0.75 (0.59-0.94) 0.014 0.67 (0.51-0.89) 0.005 0.64 (0.52-0.78) < 0.001 0.66 (0.52-0.83) < 0.001
Post-RT immunotherapy
 No 1 (reference) - 1 (reference) -
 Yes 0.88 (0.59-1.31) 0.528 - - 1.25 (0.90-1.74) 0.188 - -
Systemic regimen change
 No 1 (reference) - 1 (reference) 1 (reference)
 Yes 0.93 (0.63-1.37) 0.715 - - 1.52 (1.12-2.08) 0.008 1.39 (0.96-2.02) 0.081
Intrathecal chemotherapy
 No 1 (reference) - 1 (reference) -
 Yes 1.50 (0.76-2.98) 0.245 - - 1.58 (0.87-2.88) 0.135 - -

ALK, anaplastic lymphoma kinase; BED, biologically effective dose; CI, confidence interval; EGFR, epidermal growth factor receptor; GKS, gamma knife radiosurgery; HR, hazard ratio; NBS-RT, normal brain-sparing radiotherapy; PD-L1, programmed death-ligand 1; ROS1, c-ros oncogene 1; RT, radiotherapy; WBRT, whole brain radiotherapy.

Table 3.
Competing risk regression analysis for leukoencephalopathy
Variable Univariable
 Multivariable
HR (95% CI) p-value HR (95% CI) p-value
Age (yr)
 < 60 1 (reference) 1 (reference)
 ≥ 60 1.26 (0.94-1.68) 0.118 1.37 (0.92-2.06) 0.126
Sex
 Male 1 (reference) -
 Female 1.29 (0.87-1.93) 0.208 - -
Previous GKS
 No 1 (reference) -
 Yes 0.87 (0.54-1.38) 0.551 - -
Previous surgery
 No 1 (reference) 1 (reference)
 Yes 0.43 (0.14-1.37) 0.155 0.40 (0.13-1.28) 0.122
No. of parenchymal metastasis
 < 10 1 (reference) -
 ≥ 10 0.87 (0.66-1.15) 0.323 - -
Max diameter of metastasis (mm)
 < 30 1 (reference) -
 ≥ 30 0.76 (0.48-1.20) 0.235 - -
Leptomeningeal seeding
 No 1 (reference) -
 Yes 0.88 (0.57-1.34) 0.54 - -
Pathology
 Adenocarcinoma 1 (reference) -
 Others 0.23 (0.03-1.59) 0.136 - -
EGFR
 Negative 1 (reference) -
 Positive 1.13 (0.74-1.75) 0.567 - -
ALK
 Negative 1 (reference) -
 Positive 0.85 (0.38-1.91) 0.701 - -
ROS1
 Negative 1 (reference) -
 Positive 0.77 (0.39-1.52) 0.456 - -
PD-L1 expression (%)
 < 1 1 (reference) -
 ≥ 1 1.00 (0.74-1.36) 0.989 - -
Radiotherapy
 NBS-RT 1 (reference) 1 (reference)
 WBRT 3.63 (1.31-10.03) 0.013 3.51 (1.27-9.71) 0.016
BED (Gy)
 ≤ 39 1 (reference) -
 > 39 0.90 (0.68-1.19) 0.461 - -
Pre-RT cytotoxic chemotherapy
 No 1 (reference) -
 Yes 0.74 (0.42-1.30) 0.298 - -
Pre-RT targeted therapy
 No 1 (reference) -
 Yes 1.41 (0.95-2.10) 0.088 - -
Pre-RT immunotherapy
 No 1 (reference) -
 Yes 0.51 (0.21-1.24) 0.136 - -
Post-RT cytotoxic chemotherapy
 No 1 (reference) -
 Yes 0.97 (0.62-1.52) 0.898 - -
Post-RT targeted therapy
 No 1 (reference) -
 Yes 1.52 (1.02-2.26) 0.039 - -
Post-RT immunotherapy
 No 1 (reference) -
 Yes 0.17 (0.04-0.67) 0.012 - -
Systemic regimen change
 No 1 (reference) 1 (reference)
 Yes 0.84 (0.20-3.47) 0.812 0.17 (0.04-0.66) 0.011
Intrathecal chemotherapy
 No 1 (reference) -
 Yes 0.89 (0.47-1.69) 0.715 - -

ALK, anaplastic lymphoma kinase; BED, biologically effective dose; CI, confidence interval; EGFR, epidermal growth factor receptor; GKS, gamma knife radiosurgery; HR, hazard ratio; NBS-RT, normal brain-sparing radiotherapy; PD-L1, programmed death-ligand 1; ROS1, c-ros oncogene 1; RT, radiotherapy; WBRT, whole brain radiotherapy.

  • 1. Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27:1345–56. ArticlePubMedPDF
  • 2. Miller M, Hanna N. Advances in systemic therapy for non-small cell lung cancer. BMJ. 2021;375:n2363.ArticlePubMed
  • 3. Preusser M, Winkler F, Valiente M, Manegold C, Moyal E, Widhalm G, et al. Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion. ESMO Open. 2018;3:e000262ArticlePubMedPMC
  • 4. Barlesi F, Gervais R, Lena H, Hureaux J, Berard H, Paillotin D, et al. Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). Ann Oncol. 2011;22:2466–70. ArticlePubMed
  • 5. Aoyama H, Tago M, Shirato H; Japanese Radiation Oncology Study Group 99-1 (JROSG 99-1). Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: secondary analysis of the JROSG 99-1 randomized clinical trial. JAMA Oncol. 2015;1:457–64. ArticlePubMed
  • 6. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10:1037–44. ArticlePubMed
  • 7. Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29:134–41. PubMed
  • 8. Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA. 2016;316:401–9. PubMedPMC
  • 9. Churilla TM, Ballman KV, Brown PD, Twohy EL, Jaeckle K, Farace E, et al. Stereotactic radiosurgery with or without whole-brain radiation therapy for limited brain metastases: a secondary analysis of the North Central Cancer Treatment Group N0574 (Alliance) randomized controlled trial. Int J Radiat Oncol Biol Phys. 2017;99:1173–8. ArticlePubMedPMC
  • 10. Sperduto PW, Shanley R, Luo X, Andrews D, Werner-Wasik M, Valicenti R, et al. Secondary analysis of RTOG 9508, a phase 3 randomized trial of whole-brain radiation therapy versus WBRT plus stereotactic radiosurgery in patients with 1-3 brain metastases: poststratified by the graded prognostic assessment (GPA). Int J Radiat Oncol Biol Phys. 2014;90:526–31. ArticlePubMedPMC
  • 11. El Gantery MM, Abd El Baky HM, El Hossieny HA, Mahmoud M, Youssef O. Management of brain metastases with stereotactic radiosurgery alone versus whole brain irradiation alone versus both. Radiat Oncol. 2014;9:116.PubMedPMC
  • 12. Brown PD, Ballman KV, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017;18:1049–60. ArticlePubMedPMC
  • 13. Hughes RT, Masters AH, McTyre ER, Farris MK, Chung C, Page BR, et al. Initial SRS for patients with 5 to 15 brain metastases: results of a multi-institutional experience. Int J Radiat Oncol Biol Phys. 2019;104:1091–8. ArticlePubMed
  • 14. Yamamoto M, Kawabe T, Sato Y, Higuchi Y, Nariai T, Watanabe S, et al. Stereotactic radiosurgery for patients with multiple brain metastases: a case-matched study comparing treatment results for patients with 2-9 versus 10 or more tumors. J Neurosurg. 2014;121 Suppl:16–25. ArticlePubMed
  • 15. Lehrer EJ, Peterson JL, Zaorsky NG, Brown PD, Sahgal A, Chiang VL, et al. Single versus multifraction stereotactic radiosurgery for large brain metastases: an international meta-analysis of 24 trials. Int J Radiat Oncol Biol Phys. 2019;103:618–30. ArticlePubMed
  • 16. Kanda T, Wakabayashi Y, Zeng F, Ueno Y, Sofue K, Maeda T, et al. Imaging findings in radiation therapy complications of the central nervous system. Jpn J Radiol. 2018;36:519–27. ArticlePubMedPDF
  • 17. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509. Article
  • 18. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113–25. PubMed
  • 19. Shaw AT, Bauer TM, de Marinis F, Felip E, Goto Y, Liu G, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383:2018–29. ArticlePubMed
  • 20. Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, et al. Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol. 2019;37:2518–27. ArticlePubMedPMC
  • 21. Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 2022;40:1301–11. ArticlePubMedPMC
  • 22. Ebi J, Sato H, Nakajima M, Shishido F. Incidence of leukoencephalopathy after whole-brain radiation therapy for brain metastases. Int J Radiat Oncol Biol Phys. 2013;85:1212–7. ArticlePubMed
  • 23. Zhong X, Huang B, Feng J, Yang W, Liu H. Delayed leukoencephalopathy of non-small cell lung cancer patients with brain metastases underwent whole brain radiation therapy. J Neurooncol. 2015;125:177–81. ArticlePubMedPDF
  • 24. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295:2483–91. ArticlePubMed
  • 25. Churilla TM, Handorf E, Collette S, Collette L, Dong Y, Aizer AA, et al. Whole brain radiotherapy after stereotactic radiosurgery or surgical resection among patients with one to three brain metastases and favorable prognoses: a secondary analysis of EORTC 22952-26001. Ann Oncol. 2017;28:2588–94. ArticlePubMedPMC
  • 26. Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys. 1999;45:427–34. ArticlePubMed
  • 27. Doherty MK, Korpanty GJ, Tomasini P, Alizadeh M, Jao K, Labbe C, et al. Treatment options for patients with brain metastases from EGFR/ALK-driven lung cancer. Radiother Oncol. 2017;123:195–202. ArticlePubMed
  • 28. Zhu Q, Sun Y, Cui Y, Ye K, Yang C, Yang D, et al. Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC). Oncotarget. 2017;8:13304–11. ArticlePubMedPMC
  • 29. Magnuson WJ, Lester-Coll NH, Wu AJ, Yang TJ, Lockney NA, Gerber NK, et al. Management of brain metastases in tyrosine kinase unhibitor-naive epidermal growth factor receptormutant non-small-cell lung cancer: a retrospective multi-institutional analysis. J Clin Oncol. 2017;35:1070–7. PubMed
  • 30. Terziev R, Psimaras D, Marie Y, Feuvret L, Berzero G, Jacob J, et al. Cumulative incidence and risk factors for radiation induced leukoencephalopathy in high grade glioma long term survivors. Sci Rep. 2021;11:10176.ArticlePubMedPMCPDF

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  

      • PubReader PubReader
      • ePub LinkePub Link
      • Cite
        CITE
        export Copy Download
        Close
        Download Citation
        Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
        Format:
        • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
        • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
        Include:
        • Citation for the content below
        Normal Brain-Sparing Radiotherapy versus Whole Brain Radiotherapy for Multiple Brain Metastasis from Non–Small Cell Lung Cancer
        Close
      • XML DownloadXML Download
      • 0
      Normal Brain-Sparing Radiotherapy versus Whole Brain Radiotherapy for Multiple Brain Metastasis from Non–Small Cell Lung Cancer
      Image
      Fig. 1. Treatment outcomes and cumulative incidence of leukoencephalopathy according to radiotherapy (RT) group. Cumulative incidence of intracranial tumor progression (A), overall survival (B), and cumulative incidence of leukoencephalopathy (C) according to RT group. Cumulative incidence of leukoencephalopathy by detailed RT technique (D). NBS-RT, normal brain-sparing radiotherapy; WBRT, whole brain radiotherapy.

      Fig. 1.

      Normal Brain-Sparing Radiotherapy versus Whole Brain Radiotherapy for Multiple Brain Metastasis from Non–Small Cell Lung Cancer
      Characteristic WBRT (n=441) NBS-RT (n=62) p-value
      Age (yr) 62 (54-68) 61 (51-70) 0.903
      Sex
       Male 201 (45.6) 27 (43.5) 0.869
       Female 240 (54.4) 35 (56.5)
      Previous GKS
       No 337 (76.4) 41 (66.1) 0.110
       Yes 104 (23.6) 21 (33.9)
      Previous surgery
       No 415 (94.1) 59 (95.2) > 0.99
       Yes 26 (5.9) 3 (4.8)
      No. of parenchymal metastasis 10 (5-28) 12 (6-32) 0.189
      Max diameter of metastasis 11.7 (6.7-20.1) 14.4 (8.2-26.1) 0.070
      Leptomeningeal seeding
       Absent 275 (62.4) 49 (79.0) 0.015
       Present 166 (37.6) 13 (21.0)
      Pathology
       Adenocarcinoma 425 (96.4) 59 (95.2) 0.718
       Others 16 (3.6) 3 (4.8)
      EGFR
       Negative 132 (29.9) 20 (32.3) 0.798
       Positive 290 (65.8) 39 (62.9)
       Unknown 19 (4.3) 3 (4.8)
      ALK
       Negative 324 (73.5) 41 (66.1) 0.763
       Positive 26 (5.9) 4 (6.5)
       Unknown 91 (20.6) 17 (27.4)
      ROS1
       Negative 263 (59.6) 30 (48.4) 0.227
       Positive 50 (11.3) 10 (16.1)
       Unknown 128 (29.0) 22 (35.5)
      PD-L1 expression (%) 1.0 (0.0-15.0) 3.5 (0.0-50.0) 0.253
      BED (Gy) 39 (37.5-47.2) 43.9 (43.9-47.2) < 0.001
      Pre-RT cytotoxic chemotherapy
       No 363 (82.3) 47 (75.8) 0.289
       Yes 78 (17.7) 15 (24.2)
      Pre-RT targeted therapy
       No 280 (63.5) 44 (71.0) 0.313
       Yes 161 (36.5) 18 (29.0)
      Pre-RT immunotherapy
       No 400 (90.7) 56 (90.3) > 0.99
       Yes 41 (9.3) 6 (9.7)
      Post-RT cytotoxic chemotherapy
       No 323 (73.2) 39 (62.9) 0.122
       Yes 118 (26.8) 23 (37.1)
      Post-RT targeted therapy
       No 228 (51.7) 36 (58.1) 0.422
       Yes 213 (48.3) 26 (41.9)
      Post-RT immunotherapy
       No 396 (89.8) 54 (87.1) 0.669
       Yes 45 (10.2) 8 (12.9)
      Systemic regimen change
       No 394 (89.3) 54 (87.1) 0.754
       Yes 47 (10.7) 8 (12.9)
      Intrathecal chemotherapy
       No 430 (97.5) 62 (100) 0.375
       Yes 11 (2.5) 0
      Variable Intracranial progression
      		 Overall survival
      Univariable
      		 Multivariable
      		 Univariable
      		 Multivariable
      HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
      Age (yr)
       < 60 1 (reference) 1 (reference) 1 (reference) 1 (reference)
       ≥ 60 0.77 (0.65-0.91) 0.002 0.68 (0.52-0.89) 0.004 1.17 (1.01-1.35) 0.034 1.28 (1.08-1.52) 0.004
      Sex
       Male 1 (reference) - 1 (reference) -
       Female 1.13 (0.89-1.42) 0.318 - - 0.98 (0.80-1.19) 0.813 - -
      Previous GKS
       No 1 (reference) - 1 (reference) 1 (reference)
       Yes 0.95 (0.72-1.27) 0.751 - - 1.50 (1.19-1.88) < 0.001 1.36 (1.04-1.79) 0.025
      Previous surgery
       No 1 (reference) - 1 (reference) 1 (reference)
       Yes 1.35 (0.85-2.15) 0.201 - - 0.53 (0.34-0.85) 0.008 0.67 (0.38-1.17) 0.157
      No. of parenchymal metastasis
       < 10 1 (reference) - 1 (reference) -
       ≥ 10 1.05 (0.89-1.24) 0.535 - - 1.09 (0.94-1.25) 0.241 - -
      Max diameter of metastasis (mm)
       < 20 1 (reference) - 1 (reference) -
       ≥ 20 1.04 (0.83-1.32) 0.726 - - 0.71 (0.57-0.88) 0.002 - -
      Leptomeningeal seeding
       No 1 (reference) - 1 (reference) 1 (reference)
       Yes 1.07 (0.84-1.37) 0.575 - - 1.34 (1.09-1.66) 0.006 1.27 (0.98-1.64) 0.069
      Pathology
       Adenocarcinoma 1 (reference) - 1 (reference) -
       Others 0.81 (0.39-1.68) 0.569 - - 1.35 (0.81-2.27) 0.253 - -
      EGFR
       Negative 1 (reference) - 1 (reference) -
       Positive 1.05 (0.82-1.36) 0.687 - - 1.05 (0.82-1.36) 0.687 - -
      ALK
       Negative 1 (reference) - 1 (reference) 1 (reference)
       Positive 0.94 (0.59-1.50) 0.797 - - 0.94 (0.59-1.50) 0.797 0.49 (0.29-0.81) 0.006
      ROS1
       Negative 1 (reference) - 1 (reference) -
       Positive 1.27 (0.88-1.84) 0.204 - - 1.27 (0.88-1.84) 0.204 - -
      PD-L1 expression (%)
       < 1 1 (reference) 1 (reference) 1 (reference) -
       ≥ 1 0.89 (0.74-1.07) 0.199 0.80 (0.61-1.06) 0.116 0.89 (0.74-1.07) 0.199 - -
      Radiotherapy
       NBS-RT 1 (reference) - 1 (reference) -
       WBRT 0.89 (0.64-1.25) 0.516 - - 1.11 (0.82-1.51) 0.492 - -
      BED (Gy)
       ≤ 39 1 (reference) - 1 (reference) 1 (reference)
       > 39 0.98 (0.83-1.16) 0.824 - - 0.77 (0.67-0.89) 0.001 0.84 (0.71-1.00) 0.047
      Pre-RT cytotoxic chemotherapy
       No 1 (reference) - 1 (reference) -
       Yes 0.82 (0.59-1.14) 0.246 - - 1.68 (1.30-2.16) < 0.001 - -
      Pre-RT targeted therapy
       No 1 (reference) - 1 (reference) -
       Yes 0.78 (0.61-0.99) 0.044 - - 0.80 (0.65-0.99) 0.042 - -
      Pre-RT immunotherapy
       No 1 (reference) 1 (reference) 1 (reference) -
       Yes 0.70 (0.44-1.11) 0.126 0.68 (0.42-1.12) 0.130 1.91 (1.36-2.66) < 0.001 - -
      Post-RT cytotoxic chemotherapy
       No 1 (reference) - 1 (reference) -
       Yes 0.96 (0.74-1.25) 0.761 - - 1.28 (1.03-1.60) 0.025 - -
      Post-RT targeted therapy
       No 1 (reference) 1 (reference) 1 (reference) 1 (reference)
       Yes 0.75 (0.59-0.94) 0.014 0.67 (0.51-0.89) 0.005 0.64 (0.52-0.78) < 0.001 0.66 (0.52-0.83) < 0.001
      Post-RT immunotherapy
       No 1 (reference) - 1 (reference) -
       Yes 0.88 (0.59-1.31) 0.528 - - 1.25 (0.90-1.74) 0.188 - -
      Systemic regimen change
       No 1 (reference) - 1 (reference) 1 (reference)
       Yes 0.93 (0.63-1.37) 0.715 - - 1.52 (1.12-2.08) 0.008 1.39 (0.96-2.02) 0.081
      Intrathecal chemotherapy
       No 1 (reference) - 1 (reference) -
       Yes 1.50 (0.76-2.98) 0.245 - - 1.58 (0.87-2.88) 0.135 - -
      Variable Univariable
      		 Multivariable
      HR (95% CI) p-value HR (95% CI) p-value
      Age (yr)
       < 60 1 (reference) 1 (reference)
       ≥ 60 1.26 (0.94-1.68) 0.118 1.37 (0.92-2.06) 0.126
      Sex
       Male 1 (reference) -
       Female 1.29 (0.87-1.93) 0.208 - -
      Previous GKS
       No 1 (reference) -
       Yes 0.87 (0.54-1.38) 0.551 - -
      Previous surgery
       No 1 (reference) 1 (reference)
       Yes 0.43 (0.14-1.37) 0.155 0.40 (0.13-1.28) 0.122
      No. of parenchymal metastasis
       < 10 1 (reference) -
       ≥ 10 0.87 (0.66-1.15) 0.323 - -
      Max diameter of metastasis (mm)
       < 30 1 (reference) -
       ≥ 30 0.76 (0.48-1.20) 0.235 - -
      Leptomeningeal seeding
       No 1 (reference) -
       Yes 0.88 (0.57-1.34) 0.54 - -
      Pathology
       Adenocarcinoma 1 (reference) -
       Others 0.23 (0.03-1.59) 0.136 - -
      EGFR
       Negative 1 (reference) -
       Positive 1.13 (0.74-1.75) 0.567 - -
      ALK
       Negative 1 (reference) -
       Positive 0.85 (0.38-1.91) 0.701 - -
      ROS1
       Negative 1 (reference) -
       Positive 0.77 (0.39-1.52) 0.456 - -
      PD-L1 expression (%)
       < 1 1 (reference) -
       ≥ 1 1.00 (0.74-1.36) 0.989 - -
      Radiotherapy
       NBS-RT 1 (reference) 1 (reference)
       WBRT 3.63 (1.31-10.03) 0.013 3.51 (1.27-9.71) 0.016
      BED (Gy)
       ≤ 39 1 (reference) -
       > 39 0.90 (0.68-1.19) 0.461 - -
      Pre-RT cytotoxic chemotherapy
       No 1 (reference) -
       Yes 0.74 (0.42-1.30) 0.298 - -
      Pre-RT targeted therapy
       No 1 (reference) -
       Yes 1.41 (0.95-2.10) 0.088 - -
      Pre-RT immunotherapy
       No 1 (reference) -
       Yes 0.51 (0.21-1.24) 0.136 - -
      Post-RT cytotoxic chemotherapy
       No 1 (reference) -
       Yes 0.97 (0.62-1.52) 0.898 - -
      Post-RT targeted therapy
       No 1 (reference) -
       Yes 1.52 (1.02-2.26) 0.039 - -
      Post-RT immunotherapy
       No 1 (reference) -
       Yes 0.17 (0.04-0.67) 0.012 - -
      Systemic regimen change
       No 1 (reference) 1 (reference)
       Yes 0.84 (0.20-3.47) 0.812 0.17 (0.04-0.66) 0.011
      Intrathecal chemotherapy
       No 1 (reference) -
       Yes 0.89 (0.47-1.69) 0.715 - -
      Table 1. Patient characteristics

      Values are presented as median (IQR) or number (%). ALK, anaplastic lymphoma kinase; BED, biologically effective dose; EGFR, epidermal growth factor receptor; GKS, gamma knife radiosurgery; IQR, interquartile range; NBS-RT, normal brain-sparing radiotherapy; PD-L1, programmed death-ligand 1; ROS1, c-ros oncogene 1; RT, radiotherapy; WBRT, whole brain radiotherapy.

      Table 2. Competing risk regression for intracranial progression and Cox proportional hazards regression analysis for overall survival

      ALK, anaplastic lymphoma kinase; BED, biologically effective dose; CI, confidence interval; EGFR, epidermal growth factor receptor; GKS, gamma knife radiosurgery; HR, hazard ratio; NBS-RT, normal brain-sparing radiotherapy; PD-L1, programmed death-ligand 1; ROS1, c-ros oncogene 1; RT, radiotherapy; WBRT, whole brain radiotherapy.

      Table 3. Competing risk regression analysis for leukoencephalopathy

      ALK, anaplastic lymphoma kinase; BED, biologically effective dose; CI, confidence interval; EGFR, epidermal growth factor receptor; GKS, gamma knife radiosurgery; HR, hazard ratio; NBS-RT, normal brain-sparing radiotherapy; PD-L1, programmed death-ligand 1; ROS1, c-ros oncogene 1; RT, radiotherapy; WBRT, whole brain radiotherapy.

      Table 1.

      Table 2.

      Table 3.

      Cancer Res Treat : Cancer Research and Treatment
      © Korean Cancer Association.
      Close layer
      TOP